3Said D, Anne A, Robert E H, et al.Cancer vaccines and immunotherapy[J]. British Medical Bulletin, 2002,62( 1 ) : 149-162.
4Jager E, Jager D, Knuth A. Antigen-specific immunotherapy and cancer vaccines [J].Int J Cancer, 2003, 106(6) :817-820.
5Lienard D, Rimoldi D, Marchand M,et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in 1FA [J]. Cancer Immun,2004,4:4.
6Vantomme V, Dantinne C, Amrani N,et al. Immunologic analysis of a phase Ⅰ/Ⅱ study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors [J]. J Immunother,2004,27(2) : 124-135.
7Kaufman H L, Wang W, Manola J, et al. Phase ii randomized study of vaccine treatment of advanced prostate cancer (E7897) : a trial of the Eastern Cooperative Ontology Group [J]. J Clin Oncol, 2004,22( 11 ) :2122-2132.
8Gulley J, Chen A P, Dahut W, et al.Phase Ⅰ study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer [J]. Prostate, 2002,53(2) : 109-117.
9Tagawa S T, Lee P, Snively J, et al.Phase Ⅰ study of intranodal delivery of a plasmid DNA vaccine for patients with Stage Ⅳ melanoma [J]. Cancer,2003,98( 1 ) : 144-154.
10Bergman P J, MeKnight J, Novosad A,et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase Ⅰ trial [J].Clin Cancer Res, 2003, 9(4):1284-1290.
4Boyano MD, Garcia-Vdzquez MD, I_6pez-Michelena T, et al. Solu- ble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukirrl0 serum levels in patients with melanoma[J]. Br JCancer,2000,83(7):847-852.
